Literature DB >> 33232688

LncRNA MALAT1/microRNA let-7f/KLF5 axis regulates podocyte injury in diabetic nephropathy.

Hu Zhang1, Yu Yan1, Qingfeng Hu2, Xiaohui Zhang3.   

Abstract

OBJECTIVE: The abnormal expression of microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) has been demonstrated to exert pivotal effects in human diseases. We focused on the functions of metastasis associated lung adenocarcinoma transcript 1 (MALAT1) and microRNA let-7f on diabetic nephropathy (DN).
METHODS: The diabetes (db/db) mice were treated with silenced MALAT1, then the baseline indicators, pathology changes, marker proteins of podocyte injury (nephrin, podocin, desmin and Cleaved caspase-3), oxidative stress indicators and inflammatory factors in renal tissues were determined. Murine podocyte MPC5 cells were stimulated by high glucose (HG) and transfected with sh-MALAT1 or let-7f mimic, then the cell migration, adhesion ability and apoptosis were evaluated. Moreover, the binding relationship between MALAT1 and let-7f, and the targeting relationship between let-7f and krüppel-like factor 5 (KLF5) were confirmed.
RESULTS: Silenced MALAT1 could improve baseline indicators of DN mice, and also improved pathology, increased nephrin and podocin expression, decreased desmin and Cleaved caspase-3 expression, and restrained oxidative stress and inflammatory reaction in their renal tissues. Additionally, elevated let-7f and reduced MALAT1 could restrict migration and apoptosis of HG-induced MPC5 cells, and promoted the cell adhesion ability.
CONCLUSION: Results in our research indicated that the reduced MALAT1 could relieve the podocyte injury in DN by upregulating let-7f and inhibiting KLF5, which may be helpful for DN therapy.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Diabetic nephropathy; Krüppel-like factor 5; Long non-coding RNA metastasis associated lung adenocarcinoma transcript 1; MicroRNA let-7f; Podocyte injury; Proliferation

Year:  2020        PMID: 33232688     DOI: 10.1016/j.lfs.2020.118794

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Transcriptome expression profiles associated with diabetic nephropathy development.

Authors:  Jing Jing; Liyuan Song; Dan Zuo; Wenyang Li; Yujing Sun; Xiaoli Ma; Jianmin Ren
Journal:  Mol Cell Biochem       Date:  2022-03-31       Impact factor: 3.396

Review 2.  Regulation of Oxidative Stress by Long Non-Coding RNAs in Vascular Complications of Diabetes.

Authors:  Pei-Ming Chu; Cheng-Chia Yu; Kun-Ling Tsai; Pei-Ling Hsieh
Journal:  Life (Basel)       Date:  2022-02-12

3.  Circulating miRNAs in extracellular vesicles related to treatment response in patients with idiopathic membranous nephropathy.

Authors:  In O Sun; Yun-Ui Bae; Kyung-Oh Doh; Soon Hyo Kwon; Haekyung Lee; Hyoungnae Kim; Jin Seok Jeon; Hyunjin Noh; Jong-Soo Choi
Journal:  J Transl Med       Date:  2022-05-14       Impact factor: 8.440

4.  Manipulation of the miR-378a/mt-ATP6 regulatory axis rescues ATP synthase in the diabetic heart and offers a novel role for lncRNA Kcnq1ot1.

Authors:  Andrya J Durr; Quincy A Hathaway; Amina Kunovac; Andrew D Taylor; Mark V Pinti; Saira Rizwan; Danielle L Shepherd; Chris C Cook; Garrett K Fink; John M Hollander
Journal:  Am J Physiol Cell Physiol       Date:  2022-02-02       Impact factor: 4.249

5.  Knockout of Bruton's tyrosine kinase in macrophages attenuates diabetic nephropathy in streptozotocin-induced mice.

Authors:  Zhe Fan; Yuanyuan Li; Lingling Xia; Yonggui Wu
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

6.  lncRNA MALAT1 Promotes Diabetic Nephropathy Progression via miR-15b-5p/TLR4 Signaling Axis.

Authors:  Zijun Yang; Dongxu Song; Yulin Wang; Lin Tang
Journal:  J Immunol Res       Date:  2022-07-21       Impact factor: 4.493

7.  miR-124-3p sabotages lncRNA MALAT1 stability to repress chondrocyte pyroptosis and relieve cartilage injury in osteoarthritis.

Authors:  Rigbat Rozi; Yubo Zhou; Kai Rong; Pingbo Chen
Journal:  J Orthop Surg Res       Date:  2022-10-15       Impact factor: 2.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.